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TRANSPORT OF GAG DIGESTING ENZYMES 
IN ENGINEERED CARTILAGE TISSUES 
YUE WANG 
ABSTRACT 
Osteoarthritis (OA) is a debilitating condition of articular cartilage that leads to pain 
and severe limitations in mobility. The generation of functional tissue-engineered cartilage 
in vitro that can be used for cartilage repair is a growing and promising OA treatment 
strategy. However, there exists a fundamental challenge in generating engineered cartilage 
which possesses native levels of cartilaginous extracellular matrix constituents 
(glycosaminoglycans [GAG] and type-II collagen) and mechanical properties, leaving 
engineered tissues inferior to their native counterparts and inherently more vulnerable to 
degeneration upon implantation in the mechanical environment of the synovial joint. In 
particular, while engineered cartilage tissues generally synthesize GAG at a rapid rate, the 
content of collagen is far more limited, compromising the tensile stiffness and long-term 
stability of engineered cartilage. 
A promising strategy has recently been developed to promote collagen enhancements 
in engineered cartilage. Here, GAG-degrading enzymes (e.g. chondroitinase, 
hyaluronidase) are administered to the tissues, which digest and suppress the accumulation 
of abundantly synthesized GAG matrix molecules, providing more room in the tissue for 
collagen deposition. While the short term exposure of high doses of these enzymes has 
exhibited measured success in enhancing tissue collagen levels, it is further associated with 
considerable limitations such as limited tissue penetration and significant loss of cell 
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viability.  
A major goal of this research project is to optimize the delivery of GAG-depleting 
enzymes to achieve sufficient levels of GAG depletion without loss of cell viability. 
However, these enzymes exhibit highly complex transport kinetics into engineered tissues, 
influenced by ECM binding interactions and activity kinetics. As such, the methodology 
to optimize the concentration and temporal exposure of these enzymes remains quite 
complex.  
In the first study of the thesis, the effect of different doses of hyaluronidase 
supplement in tissue engineering is investigated. In the following chapter, an optimized 
fluorescent conjugation to hyaluronidase to maintain functionality is studied, then the 
transport distributions of the hyaluronidase in live tissue constructs are observed. The 
results demonstrate that fluorophore labeled hyaluronidase with a degree of labeling of 1 
still remain 90% functionality. And the GAG content and cell viability in constructs are 
vary after being treated with hyaluronidase of different concentration. These results pave 
the path for future development of the application of hyaluronidase in cartilage tissue 
engineering. 
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CHAPTER ONE Introduction 
Articular cartilage is the hyaline soft tissue that overlies the articulating bony ends in 
diarthrodial joints, functioning as a low-friction, load-bearing, wear-resistant material that 
facilitates joint motion1,2. It has been widely known that articular cartilage lesions have a 
limited capacity for regeneration and self-repair3, which may lead to osteoarthritis, a 
debilitating condition of articular cartilage that leads to pain and severe limitations in 
mobility. In a study of arthroscopies done in patients who experience knee pain13, articular 
cartilage changes were marked in 66% of the knees, and isolated, localized cartilage lesions 
were noted in about 20% of the cases. Full thickness cartilage lesions were found in 11% 
of the knees. In consequence, developing treatment of articular cartilage injuries has 
become significantly important. 
Motivated by this situation, a number of strategies have been proposed to develop 
functional tissue-engineered cartilage for implantation. However, there is a fundamental 
challenge in generating engineered cartilage which possesses native levels of cartilaginous 
extracellular matrix constituents (glycosaminoglycans (GAG) and type-II collagen) and 
mechanical properties. While recent researchers have demonstrated that the synthesis of 
glycosaminoglycans (GAG), can reach up to native levels in 4-6 weeks of in vitro culture, 
the content of collagen is far more limited, compromising the tensile stiffness and long-
term stability of engineered cartilage since collagen provides the tensile stiffness and 
strength of articular cartilage and contributes to the cohesiveness of the tissue by 
mechanically entrapping the large proteoglycans.1,4,5,7.  
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Several collagen enhancement techniques have been investigated regarding this 
problem such as soluble factors supplement (Thyroid hormones), scaffold removal51,52. 
Moreover, researchers have attempted to administer GAG-degrading enzymes (e.g. 
chondroitinase) to the tissue, which digest and suppress the accumulation of abundantly 
synthesized GAG matrix molecules, providing more room in the tissue for collagen 
deposition. While the short-term exposure of high doses of these enzymes has exhibited 
measured success in enhancing tissue collagen levels, it is further associated with 
considerable limitations such as significant loss of cell viability7. As such, the methodology 
to optimize the concentration and temporal exposure of these enzymes remains quite 
complex. An ideal strategy would achieve short term suppression of GAG deposition 
without any interference with cell viability of functionality. After an intact collagen matrix 
has been deposited, the enzyme exposure can be released, allowing for the recovery of 
native GAG levels in the tissue. Overall, this approach can potentially led to the 
development of engineered tissues with native levels of both GAG and collagen, allowing 
for tissues with suitable mechanical functionality upon implantation in the synovial joint. 
1.1 Aims and Hypothesis of Investigation 
In this dissertation, we investigated the ability of a different type of GAG-depleting 
enzyme, hyaluronidase, to inhibit GAG accumulation in tissue constructs. Hyaluronidase 
digests hyaluronic acid instead of chondroitin sulfate. We anticipate that hyaluronidase 
may have less of an impact on chondrocyte viability loss. It is hypothesized that the 
supplement of hyaluronidase will deplete GAG content so that the secretion of collagen 
would be enhanced. And the GAG content is expected to come back after a period of in 
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vitro culturing without supplement of the enzyme. On the other hand, we also investigated 
the transport of hyaluronidase in engineered tissues. 
1.2 Structure of Thesis 
Chapter 2 describes the background information including 1) Articular cartilage, 2) 
Tissue engineering, 3) Glycosaminoglycan-degrading enzymes, 4) Fluorescent labeling in 
molecules tracking. Chapter 3 details the investigation of the effects on tissue-engineered 
cartilage of varying doses of hyaluronidase, including mechanical and biochemical 
properties, and cell viability. Chapter 4 describes different methods on labeling 
hyaluronidase with dyes and the transport of hyaluronidase on living tissue constructs. In 
the last, chapter 5 summarizes the study and propose some suggestions for future work. 
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CHAPTER TWO Background 
2.1 The Composition and Structure of Articular Cartilage 
Articular cartilage is the hyaline soft tissue that overlies the articulating bony ends in 
diarthrodial joints, functioning as a low-friction, load-bearing, wear-resistant material that 
facilitates joint motion1,2. It is, unlike other tissues, devoid of nerves, lymphatics and blood 
vessels. Importantly, articular cartilage has a limited capacity for intrinsic regeneration and 
self-repair, which equates its preservation and health to joint health3. 
Articular cartilage is composed of a small percentage of chondrocytes, which is the 
only cell type in articular cartilage, and a dense extracellular matrix (ECM) immobilizes 
the cells and endows the cartilage with mechanical properties1,10,11. In engineering term, 
articular cartilage is a porous, viscoelastic material consisting of two principle phases: 1) 
fluid phase composed of water and electrolytes; 2) solid phase including collagen, 
proteoglycans, other proteins and chondrocytes1,2. 
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Table 2.1  Composition of Articular cartilage10 
Proteoglycans (PGs) are large complex molecules consist of a protein core to which 
one or more glycosaminoglycan chains (chondroitin sulfate and keratan sulfate) are 
covalently attached to form a bottlebrush-like structure1,11,14. In the case of articular 
cartilage, the large aggregating PGs, aggrecan, is the major component of the matrix. 
Aggrecan is characterized by its ability to bind to a backbone of hyaluronate to form a large 
proteoglycan aggregates via link proteins11,14 (Figure 2.1) and endows the cartilage with 
ability to resist compressive loads1,3. Basically, the sulfate and carboxyl groups on GAG 
chains become negatively charged in solution and in situ1,14. These negatively charged sites 
are pushed closer together when cartilage is compressed, increasing their mutual repulsive 
force and adding to the stiffness of the cartilage1,15,16. 
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Figure 2.1 Diagram of proteoglycan aggregation15 
Collagen is a fibrous protein that exists most abundantly in ECM and makes up 60-
70% of the dry weight of cartilage3,14. There are at least 20 different collagen types that 
have been identified so far17,18. All members of collagen family consist of a right-handed 
triple helical collagenous domain formed by three polypeptide α chains1,3. Collagen can be 
classified on the basis of the polymeric structures they form or related structural 
features19,20. In articular cartilage, type II collagen represents 90-95% of the collagen in the 
ECM4,19,20. The primary function of collagen is to provide the tensile stiffness and strength 
for the tissue1,19,20. The entangling collagen frame work in the cartilage matrix can limit the 
volume of proteoglycan aggregates, which enable it to resist the swelling pressure of 
proteoglycans and the tensile stresses developed in the tissue (Figure 2.2) 1,4. 
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Figure 2.2 A schematic diagram indicating the collagen–proteoglycan matrix in 
cartilage21 
The structure and composition of articular cartilage are heterogeneous along with the 
depth1,3. Traditionally, it is defined in terms of four zones from surface to the subchondral 
zone: superficial zone, intermediate zone, deep zone, and calcified zone (Figure 2.3)14,22. 
Along with the difference of the depth, the proteoglycan network, collagen fiber, water 
content and chondrocyte shape and size are all various1,2,14. A primary goal of cartilage 
tissue engineering is to recapitulate tissues with the complex organization of native 
articular cartilage so they can exhibit long term survival upon implantation in the native 
environment. This requires a successful elaboration of both the GAG and collagen ECM. 
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Figure 2.3 Schematic of arrangement of zones in articular cartilage 
2.2 Cartilage tissue engineering 
Cartilage tissue engineering aims primarily at restoring the function of cartilage 
through the substitution of living elements23,24. Recently it has emerged as a new strategy 
involving cells, scaffolds, and bioactive factors either alone or in various combinations25. 
To create new tissue, three strategies have been widely adopted: Isolated cells or cell 
substitutes, tissue-inducing substances, cells placed on or within matrices26,27. 
The first essential component for cartilage tissue engineering is to get autologous 
chondrocytes, which often requires handling of isolated cells. Tissue samples have to be 
digested first by enzyme such as proteinase K to get rid of extracellular matrix components. 
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Avoiding contamination or potential infection is the necessary when executing all the 
steps27,28. 
Scaffolds are another important component in tissue engineering. They are generally 
three-dimensional structures that are able to provide transient support to cells for their 
growth and differentiation23,29. Generally, scaffolds used in tissue engineering can be 
classified into two major kinds: natural polymers, including collagen, fibrin, alginate, 
agarose, hyaluronan, chitosan, etc.; synthetic polymers including polyethylene glycol 
(PEG), poly(glycolic acid) (PGA), poly(lactic acid) (PLA), and poly(lactic-co-glycolic 
acid) (PLGA) copolymers23,25. Nature-derived scaffolds usually have good 
biocompatibility and cell adhesive ability, but weak mechanical properties and unstable 
degradation rate are their common drawbacks; synthetic polymers usually have poor cell 
adhesive ability, but their mechanical properties, microstructure, and degradation can be 
designed29-31. 
A major challenge in tissue engineering is while the synthesis of glycosaminoglycan 
(GAG) can reach up to native levels, the collagen content is far more limited4,5, 
compromising the tensile stiffness and long-term stability of engineered cartilage. 
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2.3 Glycosaminoglycan-degrading enzymes in tissue engineering  
2.3.1 Chondroitinase-ABC 
Chondroitinase-ABC(CABC) is a kind of enzyme that specifically depolymerize a 
variety of GAG substrates, including chondroitin sulfate, dermatan sulfate, and hyaluronic 
acid (HA)32,33,36,37, without affecting collagen network arrangement and link protein34,35. In 
cartilage tissue engineering, CABC has been used to depleting GAG content which is 
usually over-produced by the constructs and limit the room for collagen. Recent studies 
have shown that continuous or transient enzyme treatment of constructs with CABC can 
improve the collagen content, increasing their tensile properties; and the GAG content of 
the treated constructs can recover quickly after 2–3 weeks of in vitro culture7. However, 
there is a strong correlation between CABC concentration and cell death. DNA results 
showed that cell proliferation was suppressed by CABC treatment and the extent of 
suppression rises with the increasing CABC treatment duration7. Also, multiple high-dose 
CABC treatments (0.15U/mL) were detrimental to cell viability, causing unrecoverable 
degradation of the construct ECM and mechanical properties7,8. 
2.3.2 Hyaluronidase 
This thesis attempts to implement novel GAG-depleting enzymatic techniques to 
inhibit rapid GAG accumulation in engineering cartilage tissues. Hyaluronidases are 
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classes of enzymes widely distributed throughout the animal kingdom. Karl Meyer 
introduced the term “hyaluronidase” to denote the enzymes that depolymerize hyaluronan 
(HA)38. Based on biochemical analysis and generated end products, hyaluronidases are 
classified into three different groups: 1) mammalian hyaluronidases, 2) hyaluronate-3-
glycanohydrolases, and 3) microbial hyaluronidases37,38, 
Mammalian hyaluronidase (testis type) can randomly cleave β-1-4 glycosidic linkages 
in HA (Fig 2.4) to yield even numbered oligosaccharides as the major end products9. It can 
also degrade chondroitin(Ch) and chondroitin sulfate(ChS), albeit at a slower rate40. The 
precise mechanism of hydrolysis of HA is still under investigation40,41. However, in order 
to degrade HA, the hyaluronidase must bind its substrate. The binding site is an elongated 
cleft traversing the enzyme (Fig 2.5), which is where HA or Ch/ChS is bound and catalyzed, 
and it is large enough to accommodate a hexasaccharide unit, the smallest HA fragment 
that can be degraded40-42. This gives us a first thought on how hyaluronidase would work 
and transport in cartilage tissues. 
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Figure 2.4 The structure of hyaluronic acid39 
  
 
Figure 2.5 The 3D structure of mammalian hyaluronidase
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2.4 Fluorescent labeling and modification of proteins 
An important component of this thesis is the use of fluorescent probes to track the 
transport of functional hyaluronidase enzymes into engineered cartilage tissues. 
Fluorescence-based assays are important experimental tools that enable the measurement 
and detailed dissection of protein interaction and enzyme activity etc.44 And the assays can 
be performed with sensitivity down to single molecules. This also allows the ability to see 
the distribution of individual proteins44-46. However, although attaching multiple labels can 
enhance the overall brightness of protein, it is likely to reduce active sites of the protein, 
compromising the functionality44,45. 
Alexa Fluor dyes are a series of dyes invented by Molecular Probes and are frequently 
used for protein labeling because of their bright fluorescence and photostability. Alexa 
Fluor 488 dye is a bright, green-fluorescent dye with excitation ideally suited to the 488 
nm laser line. It can be attached to proteins at high molar ratios without significant self-
quenching, enabling brighter conjugates and more sensitive detection47. 
Cyanine3 (Cy3) is another kind of dye that has been widely used for protein 
labeling. It has an excitation maximum of 548nm and an emission maximum of 563nm. 
Sulfo-Cyanine3 NHS ester (Figure 2.6) can efficiently labels proteins in purely aqueous 
solution, without need for organic co-solvent. The application of fluorescent labeling 
technique makes it possible to investigate the transport of the enzyme in tissues.
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Figure 2.6 The chemical structure of Sulfo-Cyanine3 NHS 
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CHAPTER THREE Dose-Dependent Effects of Hyaluronidase on Engineered 
Articular Cartilage Growth  
3.1 Introduction 
In recent years hyaluronidases have received attention and importance due to their 
regulatory function in HA metabolism9. In this dissertation, it is hypothesized that 
hyaluronidase, when supplemented in tissue engineering, can also digest GAG content in 
constructs like CABC but is less detrimental to cell viability. Here hyaluronidase treatment 
was administered to the tissues to digest and suppress the accumulation of abundantly 
synthesized GAG matrix molecules, providing more room in the tissue for collagen 
deposition. And after a period of culturing without supplement of hyaluronidase, it is 
expected that GAG content would recover to untreated level and collagen content would 
be enhanced. The doses of hyaluronidase were selected from a very high concentration   (10 
Unit/mL) where the loss of cell viability should be significant to a very low level   (0.001 
Unit/mL) where GAG could not be digested. And the dose-dependent effects were 
investigated.  
3.2 Materials and Methods 
Sample preparation and tissue culture 
Chondrocyte-seeded agarose hydrogel disks were prepared according to former 
study43. Briefly, cartilage tissues were harvested from young bovine carpometacarpal joints 
(Green Village Packing Co), and digested via 4.5mg/mL collagenase (Worthington 
Biochemical Corporation, Lakewood, NJ) at 37℃ for eight hours. Cells suspension was 
filtered and centrifuged at 1000×g for 15 minutes, and seeded in 2% agarose (Type VII, 
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Sigma, St. Louis, MO) at density of 30×106 cells/mL. Constructs (Ø3×1.9mm) were cored 
from the slabs and cultured at 37℃ in chondrogenic medium (DMEM, 1% ITS+Premix, 
50 mg/mL L-proline, 0.1 mM dexamethasone, 0.9mM sodium pyruvate, and antibiotics), 
supplemented with 10ng/mL TGF-β3(R&D Systems) only for the first two weeks. Medium 
was replenished three times a week.  
Hyaluronidase treatment 
Hyaluronidase was added into the culture media in 10, 1, 0.1, 0.01, 0.001U/mL. For 
each concentration, two delivery strategies were applied, 1) hyaluronidase was 
supplemented continuously during the study (continuous group), or 2) hyaluronidase was 
only supplemented for the first 45 days (release group), where constructs were cultured in 
the same chondrogenic media with continuous group after 45 days’ cultivation. The control 
group had no supplement of hyaluronidase. Constructs were collected on day 14, 28, 45, 
and 90 for mechanical and biochemical analyses and on day 45 for cell viability. 
Mechanical Testing 
The compressive Young’s modulus (EY) of constructs was measured at selected time 
points using a custom testing device. Briefly, constructs were subjected to unconfined 
compression in PBS via a non-porous platen, 10% strain was applied in the rate of 1μm/s, 
and 600s of relaxation was performed to reach equilibrium, compressive Young’s modulus 
was calculated by dimensions, equilibrium stress and applied strain.  
Biochemical Analysis 
Constructs were weighed and digested by 0.5 mg/mL Proteinase-K for 16 hours at 56℃ 
water bath. Sulfated GAG (sGAG) content was measured from digested aliquots by 1,9-
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dimethylmethylene blue (DMMB) dye-binding assay and normalized by the wet weight of 
construct. 
Cell Viability 
Small constructs were cut into thin slices (~100 μm) along vertical orientation, then 
processed by live/dead viability/cytotoxicity assay (Invitrogen) and imaged using confocal. 
microscopy (Olympus) to evaluate cell viability. 
3.3 Results 
 
Figure 3.1.  GAG content of constructs at day 45 
The result of biochemical composition analysis is showed in Figure 3.1. For control 
group where no hyaluronidase was administered, the amount of GAG content in constructs 
reached to 1.23±0.18mg. For lower hyaluronidase supplement groups (0.001-0.1U/mL), 
the GAG amount were not suppressed and close to control group (1.26±0.02mg, 
1.47±0.17mg, 1.19±0.16mg, respectively), which means the enzyme did nothing in these 
groups. When the concentration of the enzyme came to 1U/mL, GAG accumulation was 
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suppressed to 0.44±0.02mg. And when concentration reached to 10U/mL, GAG amount 
was significantly suppressed to 0.03±0.003mg. 
 
Figure 3.2 Compressive Young’s modulus (EY) of constructs at day 45 
The compressive Young’s Modulus analysis at day 45 (Figure 3.2) is consistent with 
the result of GAG assay. When no hyaluronidase was added (control group), constructs 
have EY of 588.53±88.45kPa. When the dose was low (0.001-0.1U/mL), constructs were 
almost as stiff as control group (411.21±98.01kPa, 495.82±120.18kPa, 422.11±53.21kPa, 
respectively). For higher concentration group (1U/mL), the EY dropped to 
138.32±43.62kPa. For the highest concentration group (10U/mL), constructs had a EY of 
22.47±3.11kPa. 
For cell viability, from confocal images (Figure. 3.3), 10U/mL group (Figure 3.3B) 
had much more dead cells than control group (Figure 3.3A). 1U/mL group (Figure 3.3C) 
also had many dead cells, comparing to the tissue without hyaluronidase exposure. For the 
rest groups (Figure 3.3D, E, F), there’s no obvious difference in cell viability. 
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Figure 3.3 Confocal images for different groups. A. Ctrl group. B. 10U/mL. C. 
1U/mL  D. 0.1U/mL.  E. 0.01U/mL.  F. 0.001U/mL. Green dots represented alive 
cells, while red dots represented dead cells. 
 
Figure 3.3 Compressive Young’s modulus (EY) of constructs at day 90 
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The compressive Young’s Modulus analysis results at day 90 is showed in Figure 3.3. 
As we can see, there is no obvious EY difference between release and continuous groups 
for all concentrations. For 10U/mL group, constucts still remained soft after 45 days 
cultivation, which suggested the GAG content did not recover. For 1U/mL group, 
constructs in both release and continuous group showed an increased EY compared to day 
45, which suggested more GAG accumulation. And constructs were almost as stiff as those 
in control group. For 0.001-0.1U/mL groups, no increase or decrease of mechanical 
properties were observed compared to control group. 
3.4 Discussion 
Our results lead us to accept our hypothesis that treatment of engineered constructs 
with hyaluronidase will lead to depletion of GAG and loss of compressive properties. In 
this study by using different doses of hyaluronidase treatment in tissue engineering, we 
discovered that when the concentration was very high (10U/mL), GAG content in 
constructs were digested significantly and compressive properties dropped sharply. 
However, it could also lead to significant loss of cell viability (Figure 3.4B), potentially 
contributing to the unrecoverable mechanical properties after 90 days in vitro culturing 
(Figure 3.3). Dose of 1U/mL treatment would preserve cell viability (Figure 3.4C). But it 
has an insufficient GAG digesting ability (Figure 3.1). On the other hand, the mechanical 
testing results showed in Figure 3.3 illustrated similar compressive properties with or 
without the supplement of hyaluronidase from day 45 to 90, which suggested a reduced 
effect of the enzyme. For lower concentrations (0.1-0.001U/mL) groups, no GAG digestion 
was observed at day 45 (Figure 3.1); no loss of cell viability was found at day 45 (Figure 
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3.4D, E, F); and no difference of compressive properties from control group were tested at 
day 45 and 90 (Figure 3.2, 3.3), which means that the enzyme showed no functionality on 
these groups. Taken together, all of these suggested that the functionality of hyaluronidase 
was limited by some unknown factors in the culturing process. One possible speculation is 
that in order to digest GAG, hyaluronidase needs to bind with it, and it takes some time for 
the enzyme to cleave it, especially when the concentration is low. When hyaluronidase was 
administered into the tissue, it was bound to the GAG in the surface of the tissues and this 
interaction had limited further penetration of the enzyme. For 1U/mL group, the enzyme 
could transport into the tissue because the concentration was high and the amount of GAG 
in constructs were very low (0.007mg, 0.05% in wet weight) at day 0. But with the 
increasing accumulation of GAG, it was harder for the enzyme to penetrate in and show its 
functionality. For 0.1–0.001U/mL groups, the concentration was just too low to get in at 
the beginning or first few days, so we saw no difference from control group. In order to 
verify the hypothesis, the transport of hyaluronidase in tissues must be investigated. 
Besides, we did not perform collagen assay just simply because it is meaningless if the 
GAG content in constructs cannot recover. 
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CHAPTER 4 Hyaluronidase labeling and transport in cartilage tissues 
4.1 Introduction 
Based on the results in Chapter 3, we realized that hyaluronidase supplementation for 
GAG digestion in tissue engineering may exhibit key limitations: the use of high 
hyaluronidase doses (10U/mL) leads to GAG suppression but also leads to a substantial 
loss of cell viability. Further, the GAG content does not return after hyaluronidase exposure 
is halted. While the alternative utilization of lower doses (1-0.001U/mL) may preserve cell 
viability, they provide insufficient GAG suppression. Explanations for this latter 
observation may be that either 1) these lower doses are unable to effectively digest 
hyaluronic acid in the tissue or 2) hyaluronidase at lower doses is transport limited; that is 
unable to effectively penetrate beyond the outer layer of the tissue constructs due to 
interactions with hyaluronic acid that is continuously synthesized and secreted by cells. In 
this chapter, we examine the second explanation using a novel analytical transport platform. 
Here, we monitor the transport of functional hyaluronidase molecule into love tissue 
constructs using fluorescent labelling. The first part of this chapter described the effort to 
effectively label hyaluronidase enzymes without compromising their functionality. 
4.2 Fluorescent labeling to hyaluronidase 
4.2.1 Materials and Methods. 
Hyaluronidase labeling 
Hyaluronidase from young bovine testes (55kDa) was purchased commercially 
(H3506; Sigma) and prepared at 1mg/mL in 0.1M sodium bicarbonate (Sigma). 
Hyaluronidase was conjugated with different dyes including cyanine3 (Lumiprobe) and 
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Alexa Fluor 488 including NHS ester and maleimide (Thermo Fisher Scientific) at molar 
ratios of 1:1, 1:3, 1:10, 1:30 in order to get different degree of labeling. Products were 
purified by multiple centrifuge. The labeled hyaluronidase was lyophilized into powder 
and stored at -30°C 
Labeling efficiency Measurement 
The degree of labeling (mol dye / mol protein) (DOL) was determined in duplicate 
protein-dye conjugate using a NanoDrop 2000 spectrophotometer (Thermo Fisher 
Scientific). Briefly, a series of fluorescent standard sets (10, 5, 2.5, 1.25, 0.67, 0.33, 0.15, 
0 ug/mL) and products diluted in a proper concentration were measured by nanodrop to get 
their absorbance. Then the fluorescent concentration of the products could be determined 
by the absorbance-concentration curve derived by standard sets. Then the DOL can be 
calculated by the concentration and molecular weight of protein and fluorophore in 
products. 
Functionality measurement 
The functionality of labeled hyaluronidase was determined by Hyaluronan DuoSet 
ELISA (R&D). This is an ELISA like system that can detect the concentration of 
hyaluronan from 0.37 to 90ng/mL. So the functionality of the fluorescent hyaluronidase 
can be determined based on how much hyaluronan it can digest. Briefly, hyaluronan stock 
was prepared in PBS at 50ng/mL, and hyaluronidases with different DOL were made into 
stock with a concentration of 100ug/mL. 20uL hyaluronidase stock was added 
independently into 500uL hyaluronan stock and reacted for 30 minutes. Then the 
concentration of hyaluronan was detected by the system. 
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4.2.2 Results 
The results of DOL and functionality testing are showed in Figure 4.1. For 1, 3, 10, 
30-fold molar excess, Alexa fluor 488-maleimide showed DOL of 0.18, 0.25, 0.37, 0.67, 
respectively; and the functionalities were 96.76%, 100%, 95.66%, 97.47%, respectively. 
Alexa fluor 488-NHS showed DOL of 0.14 0.46, 1.22, 1.83 and functionalities of 94.82%, 
93.11%, 86.35%, 57.90%, respectively. Cy3 showed DOL of 0.46, 1.326, 2.447, 4.843, and 
functionalities of 95.05%, 86.78%, 56.35%, 8.11%, respectively. 
 
Figure 4.1 The functionality of labeled hyaluronidase versus degree of labeling 
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4.3 Hyaluronidase transport distribution in engineered living tissues 
4.3.1 Materials and Methods 
Experimental Samples Fabrication and Cultivation 
The samples used in this study are constructs at day 0, for which the procedure was 
described in last chapter. Hyaluronidase and bovine serum albumin (BSA) were labeled 
with Fluorescein-5-Isothiocyanate (FITC), a counterpart of Alexa Fluor 488 that is a little 
bit dimmer but much cheaper. The fluorescent hyaluronidase (with DOL of around 1, which 
can better demonstrate the transport of the enzyme since every molecule of hyaluronidase 
has a fluorophore on average) were lyophilized into powder and were prepared to stocks, 
and then supplemented in chondrogenic medium at concentration of 10, 1, 0.1, 0.01ug/mL 
(comparable to the concentrations used in tissue engineering). Fluorescent BSA was also 
added to the medium at 10ug/mL as control group. Constructs were placed in medium of 
which the volume was 20-fold of construct. Then they were incubated at 37°C in incubator 
for 4 hours. Medium was made freshly and changed once a day. After culturing, constructs 
were cut into thin slices (~100 μm) along vertical orientation and imaged using confocal 
(Olympus). 
Data processing 
The confocal images were plotted into gradient diagrams which demonstrated the 
change of fluorescent intensity with position. All the diagrams were normalized and 
combined into one gradient diagram. The process of normalization is stated as follows: the 
intensity in the deepest part of the image was regarded as background caused by unfiltered 
fluorophore and subtracted by each data. The highest intensity was set as 0 micron and 100% 
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intensity. Data were collected every 24.85 microns (10 pixels). 
 
 
 
 
 
Figure 4.2 Confocal images and gradient diagram for constructs and explants.  A. 
constructs in 10ug/mL group. B. constructs in 0.01ug/mL group. C. constructs in BSA 
group.  For confocal images, the green dots in confocal images represented fluorescent 
labeled protein. For the gradient diagrams, the Y-axis represented the intensity of the 
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fluorescence and the X-axis represented position, the intensity of unbounded 
fluorophore was deducted. 1 pixel = 2.485 microns. 
 
 
Figure 4.3 Normalized gradient diagram for constructs and explants. 
4.3.2 Results 
The confocal images and gradient diagrams are showed in Figure 4.2. For 
experimental groups, hyaluronidase accumulated mostly on the surface, and the 
concentration of hyaluronidase decreased as it tried to diffuse further (Figure 4.2 A1, B1). 
For control group, there was no gradient observed (Figure 4.2 C1). 
 The normalized gradient diagram showed that within 124.25 microns (50 pixels), the 
intensity for constructs in 10, 0.01ugmL, and explants in 10ug/mL dropped to 57.63, 51.69, 
5.33, respectively. Within 248.5 microns (100 pixels), the intensity for each group are 41.03, 
3.68, 1.59. Within 500 microns (200 pixels), the Intensity became 21.73, 0.09, 2.01. 
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4.4 Discussion 
In the first part of this study, the results demonstrated that hyaluronidase can still have 
functionality after fluorescent labeling if the DOL is proper. And the functionality is related 
to the degree of labeling: the higher the DOL, the lower the functionality. For Alexa fluor 
488-maleimide, the DOL is pretty low because its targets are free thiols on protein and 
there are limited free thiols on hyaluronidase. For Alexa fluor 488-NHS and cy3, both of 
them can reach a higher DOL as NHS group and Cy3 react with free amine and the number 
of free amine on hyaluronidase is much more. Hyaluronidase labeled with Alex NHS and 
Cy3 can maintain a good functionality when DOL is around 1, while lost functionality 
sharply when DOL increased. The reason of it might be that when too many fluorophores 
conjugate with hyaluronidase, some of the fluorophores might block functional sites of 
hyaluronidase, leading to functionality loss.  
In the second part, the results confirmed the hypothesis that the hyaluronidase 
transport is related to the interaction between it and GAG content. It is obvious that there 
is a distribution gradient of hyaluronidase in tissue constructs, ignoring its concentration 
The reason might be that hyaluronidase, when administered into the tissue constructs, 
bound and depolymerized GAG in the tissues, which limited the transport of the enzyme. 
This penetration limitation will affect its effect of GAG digestion in our Chapter 3. For 
10ug/mL hyaluronidase, the results of mechanical and biochemical properties in Chapter 3 
indicated that it could digest most GAG in tissues, thus, it might, given enough time, have 
the ability to penetrate into the constructs to digest the GAG both on surface and in deeper 
locations. However, hyaluronidase at lower doses is transport limited; that is unable to 
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effectively penetrate beyond the outer layer of the tissue constructs due to interactions with 
hyaluronic acid that is continuously synthesized and secreted by cells. In Figure 4.2 B1 we 
can see that when the concentration of hyaluronidase is 0.01ug/mL, most of them were 
bound to the surface of the constructs. Although in Figure 4.3 the drop of the curve for 
0.01ug/mL group is slower than that of 10ug/mL, we believe that is just because of the 
over-saturated confocal image. And the truth that the intensity decreased from a relatively 
high value to around zero from 124.25 to 248.5 pixel also suggested that it is harder for the 
enzyme to penetrate further when the concentration is low. Besides, constructs used for this 
experiment is at day 0, where there was not much ECM inside. And the amount of ECM 
would increase quickly with culturing, which make this transport process even harder. This 
accounts for the results showed in Chapter 4 that neither the EY nor the content of GAG 
decreased for low concentration groups. The control group demonstrated that BSA, a 
protein that has no interaction with ECM, could easily penetrate into the tissue and there is 
no apparent distribution gradient, which represents that the fluorophore itself would not 
affect the gradient of hyaluronidase penetration. 
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CHAPTER 5 Conclusion 
This thesis demonstrated two studies regarding the GAG depleting enzyme, 
hyaluronidase. In the first study, hyaluronidase with different dose was administered into 
engineered cartilage constructs to investigate the optimal hyaluronidase delivery regimen 
to introduce GAG depleting effects without losing too much cell viability. The results 
described that although a concentration of 10U/mL could effectively suppress the 
accumulation of GAG, it was so high that it could lead to significant cell death and 
irrecoverable GAG content and mechanical properties. While the alternative utilization of 
lower doses (1-0.001U/mL) may preserve cell viability, they provide insufficient GAG 
suppression. In the second study, an optimized fluorescent conjugation to hyaluronidase to 
maintain functionality was investigated. Then the transport distributions of the 
hyaluronidase in explants and live tissue constructs were observed. The results showed the 
functionality of fluorescent labeled hyaluronidase is related to the degree of labeling. The 
higher the DOL, the lower the functionality of enzyme. And a DOL of around 1 (which is 
best for the investigation in this dissertation) would keep the enzyme around 90% 
functionality. And the transport investigation further helped to explain the results in the 
first study. Hyaluronidase, when supplemented with a low dose, would be hard to penetrate 
into the constructs and deplete GAG content.  
For future study, the effect of hyaluronidase treatment on constructs with different 
size should be studied, and more methodology of hyaluronidase treatment such as transient 
treatment would be investigated to realize the depletion and recovery of GAG content and 
create engineered cartilage in good quality with mechanical and biochemical properties. 
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